Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering a clinical-stage biotech filing can feel like running a lab experiment without the protocol. Vor Biopharma’s 10-K spans pages of gene-editing details, cash-burn tables, and licensing clauses that leave many investors asking, “Where do I start?”
Stock Titan answers with AI-powered clarity. Our platform scans every new document the second it lands on EDGAR—whether it’s an 8-K material events notice on fresh trial data or a Form 4 insider transaction that hints at executive sentiment. Type a natural question like “understanding Vor Biopharma SEC documents with AI” or “how to read the Vor Biopharma annual report 10-K simplified,” and get plain-English summaries, key financial metrics, and direct page links within seconds.
Here’s what you can explore in one dashboard:
- Vor Biopharma quarterly earnings report 10-Q filing—AI highlights shifts in R&D spend and runway.
- Vor Biopharma insider trading Form 4 transactions—real-time alerts on buys, sells, and option grants.
- Vor Biopharma proxy statement executive compensation—breakdowns of equity awards tied to clinical milestones.
- Vor Biopharma 8-K material events explained—speed-read summaries of trial pauses, FDA designations, or financing rounds.
Need deeper context? Our AI cross-references historical filings for trendlines, delivering a concise Vor Biopharma earnings report filing analysis with year-over-year R&D and dilution impacts. Investors monitoring “Vor Biopharma Form 4 insider transactions real-time” or evaluating risk factors no longer have to sift through biotech jargon—Stock Titan surfaces what matters so you can focus on decisions, not documents.
Vor Biopharma (VOR): Insider share sales reported by 10% owner/director affiliates. Entities associated with RA Capital reported open-market sales of common stock on three dates. On 10/23/2025, 76,880 shares were sold at $28.01 (weighted average). On 10/24/2025, 53,345 shares were sold at $28.01 (weighted average). On 10/27/2025, 90,941 shares were sold at $28.12 (weighted average).
After these transactions, 1,180,060 shares were beneficially owned indirectly. The filing identifies the reporting persons as RA Capital Management, L.P., RA Capital Management GP, LLC, RA Capital Healthcare Fund, L.P., and individuals including Dr. Peter Kolchinsky and Mr. Rajeev Shah, with holdings held directly by the Fund. Footnotes note weighted-average pricing across ranges and that certain parties disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) insiders affiliated with RA Capital reported open‑market sales of common stock on 10/20/2025 and 10/21/2025. Transactions included 70,366 shares at a weighted average price of $29.63 (range $29.045–$30.025), 6,553 shares at $30.12 (range $30.05–$30.26), and 25,027 shares at $28.11 (range $28.00–$28.475) held indirectly by the RA Capital Healthcare Fund. The RA Capital Nexus Fund sold 13,817 shares at $29.63 and 1,287 shares at $30.12.
Following these transactions, the Healthcare Fund beneficially owned 1,401,226 shares indirectly; the Nexus Fund held 0 shares. The filing was made by more than one reporting person. Reporting persons are noted as Director and 10% Owner and disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock. On 10/17/2025, sales included 24,689 shares at a weighted average price of $30.2207 (executed in multiple trades ranging from $30.00–$30.88) and a separate trade of 1,028 shares at $31.00. Additional sales were 11,616 shares on 10/20/2025 at a weighted average price of $30.0535 (range $30.00–$30.27) and 200 shares on 10/21/2025 at $30.075.
Following these transactions, the filing reports 1,166,909 shares beneficially owned. The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.
Vor Biopharma (VOR): Form 4 insider sales reported. A reporting group including Reprogrammed Interchange LLC sold a total of 73,676 shares of Vor Biopharma common stock on 10/15/2025 and 10/16/2025. The transactions were executed at weighted average prices of $31.0496, $32.0459, $32.7733, and $30.4548.
Following these sales, 1,204,442 shares were beneficially owned as reported after the final transaction. The securities are held by Reprogrammed Interchange LLC; per the disclosure, Reid Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest, and he disclaims beneficial ownership except to the extent of his pecuniary interest. Each sale was executed in multiple trades within disclosed price ranges.
Vor Biopharma (VOR) disclosed insider sales by affiliates of RA Capital on multiple dates. The filing lists open-market sales (Code S) on 10/15/2025, 10/16/2025, and 10/17/2025 at weighted average prices within disclosed ranges. Examples include sales at $30.55 and $31.17 on 10/15, at $29.32 and $30.36 on 10/16, and at $29.12, $30.28, and $31.00 on 10/17.
Following the reported transactions, the table shows beneficially owned amounts of 1,503,172 shares for the Fund and 15,104 shares for the Nexus Fund, each reported as indirectly held. The report notes the issuer’s 1-for-20 reverse stock split on September 18, 2025, and that the reporting persons are identified as a Director and 10% Owner.
Vor Biopharma (VOR) insider filing reports open‑market sales by an affiliate of director Reid Hoffman totaling 96,657 shares across 10/10–10/14/2025, executed at weighted average prices disclosed in the filing. Following these transactions, 1,278,118 shares were beneficially owned.
The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his interest. The filing was made by more than one reporting person.
Amendment No. 6 to Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman jointly beneficially own 1,374,775 shares of Vor Biopharma Inc., representing
Vor Biopharma Inc. (VOR) insiders reported multiple open-market sales of common stock on
Amendment No. 5 to a Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 1,498,921 shares of Vor Biopharma Inc., representing 21.9% of the outstanding common stock. The amendment discloses open-market sales that reduced the Reporting Persons' stake by more than one percent: 70,763 shares sold on
Vor Biopharma Inc. reporting persons Reprogrammed Interchange LLC and Reid Hoffman disclosed multiple open-market sales of common stock on
The document clarifies that the reported prices are weighted averages from multiple trades and that Mr. Hoffman may be deemed an indirect beneficial owner of the shares held by Reprogrammed but disclaims ownership except for his pecuniary interest. Signatures for Reid Hoffman and Frank Huang (Manager of Reprogrammed Interchange LLC) appear with dates of
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
